The present disclosure relates to combinations of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

The present disclosure relates to combinations of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

The present disclosure relates to combinations of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

The present disclosure relates to combinations of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

The present disclosure is directed to use of RORγt inhibitors in the treatment of autoimmune disorders, e.g., autoimmune disorders of the skin. This disclosure is also directed to pharmaceutical compositions comprising an RORγt inhibitor and a pharmaceutically acceptable carrier for topical administration.

The present disclosure is directed to use of RORγt inhibitors in the treatment of autoimmune disorders, e.g., autoimmune disorders of the skin. This disclosure is also directed to pharmaceutical compositions comprising an RORγt inhibitor and a pharmaceutically acceptable carrier for topical administration.

Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequinar and an immune checkpoint inhibitor. This disclosure provides a method for redirecting early myeloid precursors away from generating MDSCs thereby reducing MDSC burden.

Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequinar and an immune checkpoint inhibitor. This disclosure provides a method for redirecting early myeloid precursors away from generating MDSCs thereby reducing MDSC burden.

The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.

The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.